Open AccessLa eritropoyetina humana recombinante reduce la disfunción sensoriomotora y el deterioro cognitivo en ratas con enfermedad renal crónica
Author(s) -
Edwin E. Reza-Zaldívar,
S. Sandoval-Ávila,
Yanet Karina Gutiérrez-Mercado,
Estefanía Vázquez-Méndez,
Alejandro A. Canales-Aguirre,
Hugo EsquivelSolís,
Ulises GómezPinedo,
Ana Laura Márquez-Aguirre
Publication year - 2017
Publication title -
neurología
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 36
eISSN - 1578-1968
pISSN - 0213-4853
DOI - 10.1016/j.nrl.2017.07.016
Subject(s) - medicine , gynecology , anemia , humanities , art
Chronic kidney disease (CKD) can cause anaemia and neurological disorders. Recombinant human erythropoietin (rHuEPO) is used to manage anaemia in CKD. However, there is little evidence on the effects of rHuEPO on behaviour and cognitive function in CKD. This study aimed to evaluate the impact of rHuEPO in sensorimotor and cognitive functions in a CKD model.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom